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Thymidine phosphorylase is an angiogenic factor primarily expressed by cancer cells, stromal cells and tumour-associated
macrophages in many human malignancies. These different types of thymidine phosphorylase-expressing cells, however, may
have a distinct place in the angiogenic process, and this question was addressed in the present study. A series of 20 normal/
hyperplastic prostate glands and 60 prostate carcinomas was investigated by immunohistochemistry, using speciﬁc antibodies
for thymidine phosphorylase (P-GF.44C), tumour-associated macrophages (CD68), endothelium (CD31) and prostate speciﬁc
antigen (ER-PR8). Thymidine phosphorylase expression by normal and hyperplastic epithelial or stromal cells occurred almost
exclusively in the context of an intense lymphocytic inﬁltrate. High thymidine phosphorylase cancer cells and thymidine
phosphorylase stromal cells expression was associated with high angiogenesis in prostate carcinomas, and this signiﬁcant
association was extended to include both tumour-associated macrophages and tumour-inﬁltrating lymphocytes. Thymidine
phosphorylase expression and tumour-inﬁltrating lymphocytes were related inversely with prostate speciﬁc antigen reactivity.
In conclusion, thymidine phosphorylase is a major angiogenic factor in prostate carcinomas and its up-regulation is likely to
occur in the context of a host immune response.
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Angiogenesis is the formation of new capillaries from a pre-existing
vascular network (Folkman, 1985). It occurs as a physiological
phenomenon in regeneration and repair, and as a pathological
process in the genesis and progression of cancer. Paracrine stimuli,
such as thymidine phosphorylase (TP) and vascular endothelial
growth factor (VEGF), released from cancer cells, stromal cells
and activated macrophages play an important role in the regulation
of tumour angiogenesis. Once activated by these stimuli, endothe-
lial cells proliferate, migrate and, eventually, differentiate into
functioning capillaries (Pinedo and Slamon, 2000). In prostate
carcinomas, as in other tumours, an increased angiogenesis,
assessed as microvessel density (MVD), is usually connected with
poor prognosis (Hall et al, 1994; Bettencourt et al, 1998; Borre et
al, 1998; Offersen et al, 1998; Strohmeyer et al, 2000a,b).
Thymidine phosphorylase is an important angiogenic stimulus
in prostate carcinomas and, as would be expected, it is associated
with high MVD (Sugamoto et al, 1999; Okada et al, 2001). The
molecule, which is also known as platelet-derived endothelial cell
growth factor (PD-ECGF), catalyses the reversible phosphorylation
of thymidine to thymine and 2-deoxy-D-ribose-1-phosphate (Fox
et al, 1995b; Grifﬁths and Statford, 1997). The mechanism of the
angiogenic activity is through generation of free radicals by the
metabolic product 2-deoxy-D-ribose which was shown to stimulate
endothelial cell migration and new blood vessel formation
(Moghaddam et al, 1997; Brown and Bicknell, 1998; Brown et al
2000). The free radicals activate expression of VEGF, interleukin-
8 (IL8) and matrix metalloproteinase-1 (MMP1) (Brown et al,
2000).
The macrophages are highly differentiated cells of the mononuc-
lear macrophage system which, after activation, assume a variety of
speciﬁc functions, including phagocytosis (Adams and Hamilton,
1984; Elsbach and Weiss, 1988; Klebanoff, 1988), antigen presenta-
tion (Auger and Ross, 1992) chemotaxis (Brown and Gallin, 1988)
and release of important secretory products. In malignant disease,
the process of macrophage activation was connected with an anti-
tumour activity (Lavnikova et al, 1996; Ragnhammar, 1996) and
stimulation of angiogenesis (Polverini and Leibovich, 1984; Arras
et al, 1998), the latter being mediated through the secretion of
extracellular matrix degrading enzymes and several angiogenic
cytokines, including the TP/PD-ECGF (Sunderkotter et al, 1994;
Leek et al, 2000). Tumour associated macrophages (TAMs) express
TP, but recruitment of activated macrophages into the tumour by
tumour cells expressing TP may also contribute to angiogenesis. A
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reported (Miyazono and Takaku, 1991).
The present study was undertaken in order to investigate the
expression, distribution and the role played by the different types
of TP-expressing cells, including TAMs and tumour-inﬁltrating
lymphocytes (TILs), in stimulating angiogenesis in prostate adeno-
carcinomas. In addition, TP expression was analysed for possible
associations with histological grade and PSA expression.
MATERIALS AND METHODS
Twenty biopsy and autopsy specimens from normal and hyperplastic
prostate glands, and sixty surgical specimens of prostate adenocarci-
noma were retrieved from the ﬁles of the Department of Pathology,
Democritus University of Thrace, Greece. The tissues had been ﬁxed
in 10% formol saline and processed through graded alcohols to paraf-
ﬁn wax. Histological diagnosis of prostate cancer was based on
haematoxylin and eosin stained sections. The Gleason system (Glea-
son, 1966) was used for histological grading. A primary and
secondary Gleason score (1 to 5) was determined for every tumour,
and the combined score (Gleason sum) was then calculated. To
obtain sufﬁcient quantities for statistical analysis, the tumours were
grouped in three categories: low grade (well differentiated) if the
combined Gleason score was 4 or less; intermediate grade (moder-
ately differentiated) if combined Gleason score were 5, 6 or 7 (3+4,
with a majority of Gleason 3 areas and a small proportion – less than
20% – of Gleason 4 components); and high grade (poorly differen-
tiated) if the Gleason sum was 7 (4+3) or above.
Immunohistochemistry
Immunohistochemistry was performed at 3 mm thick formalin-ﬁxed,
parafﬁn-embedded sections with monoclonal antibodies to: angio-
genic factor TP, pan-endothelial antigen CD31, TAMs, and prostate
speciﬁc antigen (PSA). Details are given in Table 1. A standard strep-
tavidin-biotin immunoperoxidase method was used. Endogenous
peroxidase activity was blocked by exposure to absolute methanol
containing 3% hydrogen peroxide. Antigen retrieval was achieved
by microwave heating. Non-speciﬁc background staining was
reduced by protein blocking agent. The primary antibodies were
applied for 75 min at room temperature. The sections were then
sequentially incubated with: (a) anti-rabbit anti-mouse antibody
(Kwik Biotinylated Secondary, Immunon, Shandon, Pittsburgh, PA,
USA) for 15 min, and (b) Kwik Streptavidin peroxidase reagent
(Immunon, Shandon, Pittsburgh, PA, USA) for 15 min. Antibody
reactivity was detected with 3,3'-diaminobenzidine (DAB) as chro-
mogen. The slides were counterstained with Mayer’s haematoxylin.
Known positive controls were included in each staining run. Omis-
sion of the primary antibody and replacement by normal rabbit
serum at the same concentration was used as negative controls.
Assessment of TP and TAMs
TP expression was assessed in epithelial cells (normal, hyperplastic
and neoplastic), stromal cells and in tumour-associated macro-
phages. The percentage of TP positive epithelial cells, i.e.,
epithelial cells with strong cytoplasmic and/or nuclear reactivity,
was recorded for each case. The median value was used to deﬁne
cases into groups of high and low TPcc reactivity.
The expression of TP by stromal ﬁbroblasts and smooth muscle
cells (TPsc) was recorded in all optical ﬁelds. The percentage of
optical ﬁelds with strong TPsc expression was recorded, and the
median value was used to deﬁne groups of high and low TPsc reac-
tivity.
The number of tumour-associated macrophages (TAMs) was
determined at 6400 magniﬁcation. Counting was performed in
three tumour areas of high macrophage concentration (hot spot
areas). The mean was calculated. Areas of necrosis were excluded
from TAMs quantiﬁcation.
Assessment of lymphocytic inﬁltration
The extent of stromal lymphocytic inﬁltration was assessed on
haematoxylin and eosin stained sections. Areas of necrosis were
excluded from this evaluation. The percentage of optical ﬁelds
(6200) with a prominent lymphocytic response in the tumour
stroma was recorded, forming the lymphocyte inﬁltration index
(LII). The median value was used to deﬁne groups of high and
low LII.
Assessment of angiogenesis
Angiogenesis was assessed by microvessel counting in three tumour
areas of high vascular density (hot spot areas) at 6200 magniﬁca-
tion. Only vessels with a well deﬁned lumen or a linear vessel shape
were taken into account. The mean of these vessel counts obtained
was the microvessel density (MVD). Using the median MVD as a
cut-off point, our cases were grouped into categories of low and
high MVD.
Statistical analysis
Statistical analysis and graphic presentation were performed using
the GraphPad Prism 2.01 package (GraphPad, San Diego, CA,
USA, www.graphpad.com). The Fisher’s exact test or the unpaired
two-tailed t-test was used for testing relationships between catego-
rical variables as appropriate. A P-value 50.05 was considered
signiﬁcant.
RESULTS
Expression of TP in normal and hyperplastic prostates
Normal and hyperplastic prostatic glands were, by and large,
unreactive to P-GF.44C (Figure 1A). However, in areas of intense
lymphocytic inﬁltration both glandular and stromal cell component
expressed TP. The expression was strong and mixed nuclear/cyto-
plasmic (Figure 1B). A similarly strong nuclear/cytoplasmic
reactivity was invariably expressed by the normal, inﬂammatory
cell free, epithelium of the adjacent seminal vesicles.
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Table 1 Details of antibodies, dilutions and antigen retrieval methods used in the present study
Primary
Dilution/incubation antigen
antibody Time Retrieval Speciﬁcity Source
CD68 1:50 (75 min
a)M W
b TAMs Dako, Denmark
JC70 (CD31) 1:20 (75 min
a)M W
b Endothelium Dako, Denmark
ER-PR8 1:50 (75 min
a)M W
b PSA Immunon-Shandon, Pittsburgh, PA, USA
P-GF.44C Supernatant (75 min
a)M W
b TP K.C. Gatter (Oxford, UK)
aAt room temperature.
b(650 watts, 365 min in citrate buffer, pH 7.4).
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TP was primarily expressed by cancer cells (TPcc), stromal cells
(TPsc), of both ﬁbroblastic and smooth muscle origin, endothelial
cells (TPec) and in tumour associated macrophages (TAMs).
Lymphocytes were also expressing TP but the extent of lymphocy-
tic positivity could not be conﬁdently assessed in the presence of
an intense stromal TP reactivity. In all cases, the pattern of TP
expression was mixed nuclear/cytoplasmic (Figure 1C).
The percentage TPcc ranged from 0 to 90%, with a median of
12.5%. Using this value as a cut off point, 30 cases were of low
and 30 cases of high TPcc reactivity.
TPsc reactivity ranged from 0 to 100% of the optical ﬁelds
examined. The median value was 20%. A high TPsc expression
(420%) was noted in 30 of the 60 cases, and was associated with
the invariable presence of TP positive TAMs (30 out of 30 cases)
and the frequent expression of TPec (12 out of 30 cases vs 0 out
of 30 cases with low TPsc reactivity) (P50.0001).
Macrophage and lymphocytic inﬁltration
The number of CD68 positive cells enumerated in each case ranged
from 5 to 55 per 6400 optical ﬁeld. The median macrophage
number (macrophage index, MFI) was 11, and the mean
value+s.d. was 19+10. Using the median value, 30 cancer cases
were of high and 30 of low MFI. The staining reaction for
CD68 was distinctive granular and cytoplasmic.
Lymphocytic inﬁltration of the tumour supporting stroma was
recorded in 0–100% (median 25%) of the 6200 optical ﬁelds
analysed per specimen (assessment of the whole specimen). The
median value was used to deﬁne the groups of high (24 cases)
and low (36 cases) lymphocyte inﬁltration index (LII).
Angiogenic correlations
The median microvessel density (MVD) was 22 (range 7–69).
Using this value cases were divided into groups of low (30 patients)
and high MVD (30 patients). The staining reaction of endothelial
cells was mixed membranous/cytoplasmic.
A high TP reactivity by cancer and endothelial cells was signiﬁ-
cantly associated with increased angiogenesis in prostate tumours
(TPcc P=0.02; TPec P=0.002) (Table 2). High LII was also linked
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Figure 1 (A) Normal prostate gland, free of lymphocytic inﬁltrates, lack-
ing TP expression from ducts, acini and stroma. (B) Normal prostatic acini,
densely inﬁltrared by lymphocytes, exhibiting nuclear and cytoplasmic TP
expression by ‘epithelial’ (basal and secretory) and stromal cells. (C) Pros-
tate carcinoma showing a strong nuclear/cytoplasmic reactivity by tumour
and tumour supporting stromal cells.
Table 2 Correlation of MVD with TP expression, macrophage and
lymphocyte index
Microvessel density
Low High P-value
TPcc
Low 20 10 0.02
High 10 20
TPsc
Low 19 11 0.06
High 11 19
TPec
No 29 19 0.002
Yes 1 11
TPcc/TPsc
Low/low 15 6 0.04
Low/high 5 4
High/low 4 5
High/high 6 15
Tpcc/MFI
Low/low 14 4 0.02
Low/high 6 6
High/low 5 7
High/high 5 13
MFI
Low 19 11 0.06
High 11 19
LII
Low 23 13 0.01
High 7 17
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and MVD, and between the number of TAMs and MVD was
marginal (TPsc P=0.06; TAMs P=0.06).
Using double stratiﬁcation for TPsc/TPcc, and TPsc/MI a signif-
icant angiogenic co-operation between TPsc and TPcc (P=0.04)
was shown, and also between TPsc and TAMs (P=0.02) (Table
2). Using continuous variable analysis, tumours with high MVD
had a signiﬁcantly higher mean MFI than those having low
MVD (mean MPI 22+12 vs 16+8; P=0.02).
MFI and TP expression
There was a signiﬁcant relationship between TPcc and TPsc expres-
sion (P=0.004; Table 3). Although prostate carcinomas with high
MFI were frequently accompanied with high TPcc and TPsc reac-
tivity, this difference did not reach the level of statistical
signiﬁcance (P=0.19). Using the MFI as a continuous variable, a
high MFI was signiﬁcantly related with TPsc reactivity (22+11
vs 16+9; P=0.04), but this was not true in the case of TPcc
although there was a similar tendency (21+11 vs 17+9;
P=0.10). Further, a strong association between high LII and high
MFI was noted (P50.0001). A high LII was also related with high
TP expression by cancer (P=0.06) and stromal cells (P=0.01).
Correlation with histological grade and PSA expression
Out of the 60 cases of prostate cancer, 19 (32%) did not show any
reactivity after staining for PSA and were considered as negative.
The remaining showed a varying degree of strong cytoplasmic reac-
tivity (range 25–100% of cells) and these cases were considered as
PSA positive.
Neither TPcc nor TPsc expression was associated with histologi-
cal grade in prostate carcinomas, but both TPcc and TPsc
expression was inversely associated with the expression of PSA
(P=0.05) (Table 4). A signiﬁcant inverse association between LII
and PSA expression was also noted (P=0.02). MFI was more
frequent in prostate tumours with high histological grade and loss
of PSA, but none of these differences was of statistical signiﬁcance.
DISCUSSION
Thymidine phosphorylase/platelet-derived endothelial cell growth
factor (TP/PD-ECGF) is a potent angiogenic molecule stimulating
endothelial cell migration and new blood vessel formation (Mogha-
dam et al, 1995). The enzyme’s angiogenic activity has been
consistently shown in a variety of human malignancies, despite
variations of its principal source of production. Thus, expression
of TP by cancer cells was shown in carcinomas of the breast
(Fox et al, 1995a; Toi et al, 1995), lung (Koukourakis et al,
1997), head and neck (Giatromanolaki et al, 1998) and stomach
(Giatromanolaki et al, 2000), whereas a predominant stromal cell
TP expression was shown in colorectal (Takebayashi et al, 1996)
and endometrial carcinomas (Sivridis et al, 1999), particularly at
the invading tumour front. In all cases, however, high TP expres-
sion was associated with high angiogenesis, irrespective of the main
source of TP production, and this was conﬁrmed by further studies
in endometrial and in non-small cell lung tumours, where cancer
cells and stromal ﬁbroblasts were independently associated with
high angiogenesis (Koukourakis et al, 1998; Sivridis et al, 2001).
Despite our general understanding, the role of TP in prostate
cancer remains inadequately studied. Sugamoto et al (1999) indi-
cated that TP levels are higher in prostate carcinomas than in
normal prostatic tissues. Okada et al (2001) found that TP is
expressed in stromal cells, but not in cancer cells, and that an
intense stromal TP reactivity in these tumours was associated with
high microvessel density. Okada’s immunohistochemical study was
performed using two monoclonal antibodies (MoAb), the HCT116
and the P-GF-44C.
The present study was based on the MoAb P-GF-44C. TP was
detected extensively (up to 90% of cells) in the nuclei and the cyto-
plasm of cancer cells in half of the 60 cases examined. The intensity
of staining was strong, and there was a direct association between
high TP expression and high angiogenesis in prostate carcinomas.
This observation contrasts the results reported by Okada’ group
(2001). P-GF-44C is a reliable and very sensitive antibody and such
a discrepancy is difﬁcult to be explained. Equally difﬁcult is the
explanation required for Okuda’s ﬁnding that normal prostates
express TP in 80% of the cases examined. In our series, normal/
hyperplastic prostate glands and stroma were persistently unreac-
tive to P-GF-44C, and a strong nuclear/cytoplasmic TP
expression became only apparent in areas of intense lymphocytic
inﬁltration, probably in the context of a chronic prostatitis.
Lymphocytes produce a variety of lymphokines, such as interferons
and interleukins, which are potent stimulators of TP expression
(Schwartz et al, 1992; Eda et al, 1993; Goto et al, 2001). Certainly,
this would explain our ﬁnding that extensive lymphocytic inﬁltra-
tion of the prostatic tumour stroma is related with strong TP
expression by cancer and stromal cells. The pathway by which
lymphocytes, or speciﬁc subpopulations of lymphocytes, trigger
the expression of TP is not clear, although there are reports impli-
cating CD4 positive cells in tumour angiogenesis (Blotnick et al,
1994) and natural killer (NK) cells in complex interactions with
angiogenic factors (Melder et al, 1996). Furthermore, a direct asso-
ciation between lymphocytic and macrophage stromal inﬁltration
was noted. These observations provide strong evidence that up-
regulation of TP in the normal, hyperplastic and neoplastic pros-
tate tissues occur in the context of a local host immune response
against inﬂammatory or tumour antigens.
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Table 3 Correlation of the histology grade and the PSA expression with
TP reactivity, MFI and LII
Grade PSA
123 P-value Negative Positive P-value
TPcc
Low 9 10 11 0.36 6 24 0.05
High 14 9 7 13 17
TPsc
Low 12 11 7 0.49 6 24 0.05
High 11 8 11 13 17
MFI
Low 12 12 6 0.18 7 23 0.16
High 11 7 12 12 18
LII
Low 13 13 10 0.66 7 29 0.02
High 10 6 8 12 12
Table 4 Association of TP expression with Macrophage and Lympho-
cyte inﬁltration index
Macrophage index Lymphocyte index TPsc
Low High P-value Low High P-value Low High P-value
TPcc
Low 18 12 0.19 22 14 0.06 21 9 0.004
High 10 18 8 16 9 21
TPsc
Low 18 12 0.19 23 13 0.01
High 12 18 7 17
LII
Low 26 10 50.0001
High 4 20
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was consistently detected in normal seminal vesicles, regardless of
the presence or otherwise of an inﬂammatory cell response. The
vesicle epithelium, however, is endowed with abundance of mito-
chondria, a rich rough endoplasmic reticulum and a prominent
Golgi apparatus suitable for a vigorous synthetic activity (Nistal
et al, 1992). Fructose, in particular, is excessively secreted by the
vesicle epithelium (Kise et al, 2000). Catalytic TP-mediated trans-
formation of thymidine to thymine results in 2-deoxyribose-1-
phosphate production (Brown et al, 2000). Given that ribose is
actively involved in fructose metabolism, a regulatory role for TP
may be anticipated in this metabolical function (Ozeki et al,
1999; Sawada et al, 2000).
It is of interest, however, that despite the general disparity
between our results and those of Okada, this group of investigators
did ﬁnd that TP expression by stromal cells is directly related to
increased microvessel density. Furthermore, we found that simulta-
neous expression of TP by cancer and stromal cells was
considerably enhanced the angiogenic activity. This synergistic
angiogenic effect of the two cellular elements is probably due to
the higher intratumoral TP levels achieved in these cases. Neverthe-
less, the oxidative stress induced by 2-deoxyribose-1-phosphate
promotes secretion of VEGF and interleukin-8 angiogenic mole-
cules (Brown et al, 2000). Both proteins are angiogenic for
prostate cancer (Strohmeyer et al, 2000b; Doll et al, 2001; Kim et
al, 2001) and may act synergistically.
Another important observation of the present study is the clear
association between the expression of TP and the accumulation of
CD68 positive macrophages (TAMs) in the tumour supporting
stroma. This ﬁnding, which is in accordance with a previous report
of ours on non-small cell lung carcinomas (Koukourakis et al,
1998), reinforces the view for a chemotactic activity of TP on
mononuclear cells (Miyazono and Takaku, 1991). TP-mediated
macrophage chemotaxia may, therefore, contribute to the angio-
genic process, as activated macrophages, apart from producing
TP, usually secrete a variety of pro-angiogenic and angiogenic cyto-
kines (Sunderkotter et al, 1994; Ono et al, 1999; White et al, 2001).
The angiogenic relevance of an intense macrophage inﬁltration of
the tumour stroma has been shown in a variety of other human
tumours including breast (Leek et al, 2000), endometrial (Hashi-
moto et al, 2000) and lung carcinomas (Takanami et al, 1999),
gliomas (Nishie et al, 1999) and malignant melanomas (Torisu et
al, 2000).
Nevertheless, the role of macrophages in the angiogenic process
is far from clear, as an angio-suppressive effect for TAMs has also
been established. Metalloelastase of macrophage origin, has been
reported as essential for the production of ‘angiostatin’, a potent
endogenous suppressor of angiogenesis (Dong et al, 1997) and
an inhibitor of tumour progression, at least in colorectal carcino-
mas (Yang et al, 2001). Furthermore, an intense inﬁltration of
TP-expressing macrophages in the tumour stroma was related to
an improved survival in patients with colorectal tumours (Saito
et al, 2000). Production of the angiogenic inhibitor thrombospon-
din 1 by angiogenic macrophages further underlines the anti-
angiogenic potential of macrophages (Di-Pietro and Polverini,
1993).
This dual angiogenic/angiosuppressor potential of macrophages
emphasises the necessity of identifying speciﬁc subpopulations of
TAMs, which may have distinct roles in the angiogenic process.
The recently reported strong association of high macrophage index
with a better post-operative outcome in prostate cancer patients
contrasts the postulated ‘angiogenic role’ of macrophages (Shimura
et al, 2000). High angiogenesis is an important variable of poor
prognosis in prostate carcinomas, as has been convincingly shown
in a large number of studies (Silberman et al, 1997; Bettencourt et
al, 1998; Borre et al, 1998; Strohmeyer et al, 2000; Mehta et al,
2001). Speciﬁc intratumoural conditions (cytokines released by
cancer cells, ﬁbroblasts or even by tumour related lymphocytes)
may form a complex code that switches on/off or even reverses
the macrophage angiogenic machinery.
Finally, the present study revealed a signiﬁcant inverse relation-
ship between PSA expression and the expression of the angiogenic
factor TP in cancer and stromal cells. Although the loss of PSA
expression is rather suggestive of cellular de-differentiation, neither
TP nor PSA was related to Gleason’s score. This lack of association
between TP and histological grade is also a feature of other malig-
nancies, including non small cell lung carcinomas and squamous
cell carcinomas of the head and neck (Giatromanolaki et al,
1997, 1998). In a previous study, we reported that PSA was asso-
ciated with low microvessel density in prostate carcinomas
(Papadopoulos et al, 2001). This suppressive effect of PSA on
angiogenesis is probably accomplished by a mechanism of convert-
ing Lys-plasminogen to biologically active angiostatin-like
fragments with an action similar to angiostatin (Heidtmann et al,
1999). However, reduced levels of TP in prostate carcinoma expres-
sing PSA suggests that additional hypotheses are needed in order to
explain the direct association of PSA with poor vascularity.
Whether suppression of the PSA-gene leads directly to an activa-
tion of the angiogenic cascade or whether PSA suppression
simply co-exists with the up- or down-regulation of angiogenesis
controlling genes requires further investigation.
In conclusion, TP is a potent angiogenic factor stimulating new
blood vessel formation in prostate carcinomas. Tumour angiogen-
esis is, primarily, induced by angiogenic stimuli released by
neoplastic cells, ﬁbroblasts and smooth muscle cells but, in addi-
tion, TAMs and inﬁltrating lymphocytes may be actively involved
in the angiogenic process, at least in a subset of carcinomas.
Thymidine phosphorylase may be a target for cytotoxic and anti-
angiogenic therapeutic strategies in prostate tumours.
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